GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q4 EPS of $0.08, $0.01 better than the analyst estimate of $0.07. Revenue for the quarter came in at $196.64 million versus the consensus estimate of $194.32 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q1 2024 revenue of $195-198 million, versus the consensus of $194.8 million.

GoodRx Holdings, Inc. sees FY2024 revenue of ~$800 million, versus the consensus of $795.2 million.

For earnings history and earnings-related data on GoodRx Holdings, Inc. (GDRX) click here.